NewLimit develops epigenetic reprogramming therapies aimed at treating age-related diseases.
This slot renders the company's funding history: dates, rounds, amounts, valuations and lead investors once populated in data/funding-rounds.json.
NewLimit has demonstrated successful epigenetic reprogramming of human cells to restore youthful function within 3 years, on track for first drug in clinical trials next year, leveraging AI-driven virtual cell models and plummeting single-cell multi-omics costs.